Viewing Opinion | StockChase
stockchase picture

Compiling comments that experts make about stocks while on public TV.

2017-02-08

Opinion for Teva Pharmaceutical (TEVA-N)

Signal Price Bias Subject Owned
DON'T BUY $32.380 BULLISH US EQUITIES Unknown

There will be a time when this will be a hero stock for someone who bought it at the low. However, that is a tough call to make. Your odds of getting it right are low. The whole space is highly political right now.

Cameron Hurst
Chief Investment Officer, Equium Capital Management

1 Comment

jordy

February 8th 2017 at 3:54pm

Teva has taken on a lot of debt to add generics. On the branded side it's more about legal battles to extend Copaxone's patents than the product itself. There is value in the company that will eventually be realized, but yeah, maybe now is not quite the right time to be a hero.


You must be logged in to comment.